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ANALYSIS
Functional foods: the case for closer evaluation
Current regulations focus on the mandatory safety evaluation of functional foods �efore    
they come to market, �ut Nynke de Jong and colleagues argue that the effects of such foods 
should also �e evaluated after they have �een launched     
health drinks in the United Kingdom is fast growing, 
with a turnover of £316m (€464; $632) in 2005.8 
Although some functional foods (table) might have 
beneficial effects on risk factors for various chronic 
and life threatening conditions, there is no proof that 
attacking these risk factors is good for general health 
in the free living population. Their main appeal may 
be particularly to worried consumers.
Possible food and drug interactions
Functional foods may influence the effectiveness of 
drugs and patients’ compliance. This can be illustrated 
by the example of phytosterol and stanol enriched 
products, which are intended for people with mildly 
raised cholesterol who do not take cholesterol lower-
ing drugs.9-12 People in this group are often unaware 
of their cholesterol value. The enriched products 
may, therefore, be eaten only by those with substan-
tially raised, and thus known, cholesterol values and 
associated higher cardiovascular morbidity, which 
inherently increases the potential for interactions with 
cardiovascular medication.
Phytosterols and stanols interact with statins to have 
an additive effect on reducing low density lipoprotein 
cholesterol values.10 13 The possible downside to this 
Functional foods are modified foods that claim to 
improve health, quality of life, or wellbeing. These 
foods are intended for use in the context of a healthy 
lifestyle or as a means to compensate for an unhealthy 
one. From society’s point of view, there are several 
potential problems—the medicalisation of our daily 
food intake, the long term safety and effectiveness of 
these foods, and the aggressive marketing and adver-
tising of these highly profitable products.1 However, 
functional foods need to be fully evaluated to make 
sure they meet current scientific and regulatory 
standards.
EU regulations
Several European Union regulations and directives 
on functional foods are currently being developed. 
Current rules focus mainly on the mandatory safety 
evaluation of new foods before they come to mar-
ket; minimum and maximum safe upper values for 
micronutrients used for fortification; lists of permitted 
substances for fortification; the registration of herbal 
products; and acceptable nutritional and health 
claims.2
One positive development has been the recent 
publication of regulations on nutrition and health 
claims. Nutritional claims can now be made only if 
the food fits a certain nutrient profile (such as below a 
predefined fat content if “low fat”). New claims can 
be issued only after being assessed and authorised 
by the European Food Safety Authority (EFSA) 
on the basis of good nutritional science.3 4 Most of 
the regulations and directives focus on evaluat-
ing safety before foods reach the supermarket, 
however—no regulations deal with aspects that 
arise after this point.
Market positioning of functional foods versus drugs
Similar to so called lifestyle drugs—drugs at the bound-
ary between lifestyle wishes and health needs, such as 
erectile stimulants, appetite suppressants, and drugs 
to help people stop smoking5—functional foods 
are designed to meet consumers’ needs and life-
style wishes.6 7 Data on sales and market dynam-
ics of functional foods are limited. An analysis 
of functional foods launched between January 
and April 2005 identified more than 200 new 
products.
Many functional foods are aimed at trying to 
improve gut health and heart health and are 
intended for people who have mild health 
problems or slight discomfort. The market for 
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interaction is that serum phytosterol concentrations 
increase during long term statin treatment,11 and con-
cern has been raised about the possible atherogenic 
effects of phytosterols.14 This is why Health Canada, 
the federal department responsible for helping 
Canadians maintain and improve their health, has 
not allowed these foods to be sold in Canada.15 16
Eating functional foods may also have detrimental 
effects on patient compliance with drug treatment; 
adherence to statins is known to be suboptimal.17 18 
People who eat phytosterol or stanol enriched foods 
may alter the dose of their statins for various reasons, 
without consulting a doctor. A lower dose of statins 
can never be compensated for by the intake of 
functional foods.
Limited postlaunch scientific data
Once functional foods come to market, limited data 
are available about their impact on the community. 
We have little understanding of the circumstances 
under which these foods are eaten, whether target 
groups are reached, and if targeted education pro-
grammes or health policies should be recommended. 
Very little is also known about exposure, long term or 
otherwise, and safety under free conditions of use,19 
and whether and how functional foods interfere 
with drugs designed for the same target.20 21 These 
problems have not been addressed even in the best 
studied of these foods—phytosterol and stanol 
enriched foods. There is no evidence that functional 
foods cause harm, but the data are limited to five to 
six years of use and a restricted number of users. 
Scientific developments at the interface between 
food and pharmacology are ongoing, so data 
supported assessments of these foods are now pos-
sible. The development of a structured postlaunch 
monitoring system has been suggested but not yet 
implemented in Europe.22
The case for postlaunch monitoring
Despite two recent reports on the subject,23 24 we are 
still uncertain about how many people buy and con-
sume functional foods and about any benefit they may 
have, so more thorough investigations are needed. If 
these foods are found to be of net benefit to public 
health, targeted education programmes and support-
ive government policy should be considered. If no 
effect or an adverse effect is identified, the associated 
health claims should be re-evaluated. New regulations 
may also be needed. 
In addition to questions about user compliance, 
problems such as the impact of compensating behav-
iour, the possible alternative use of drugs or more tra-
ditional foods, and the effect size of these approaches 
should also be evaluated and compared. 
Postlaunch monitoring, which consists of several 
phases spread over time—starting with signalling and 
ending with a risk-benefit analysis (figure)—could 
deal with these uncertainties. Signalling could be 
performed transparently by manufacturers under 
supervision of and in collaboration with national 
food safety authorities. An EFSA committee could 
be mainly responsible for distributing monitoring 
tasks to national food safety bodies or nutrition 
research institutes, with national policymakers and 
risk managers as important intermediaries. Each 
monitoring question would determine which institute 
is assigned a particular task. Such a strategy would 
also mean close collaboration with those responsible 
for pharmacovigilance. 
The ultimate result of postlaunch monitoring could 
be a decision support tool that helps policymakers and 
others such as health insurance companies evaluate 
the impact of health promoting strategies (traditional 
foods, drugs, functional foods). Intermediaries, such 
as doctors and dietitians, should be informed about 
the results so they can educate and help consumers. 
Practical and unbiased information on when and 
how to use functional foods and potential side effects 
and interactions could be conveyed in instruction 
leaflets, reference books, and on websites. In turn, the 
intermediaries could provide feedback on consumer 
experiences to the monitoring team. This would make 
the best possible use of the results of monitoring and 
extend their coverage, so that funding for postlaunch 
monitoring might come not only from manufacturers, 
but also from national and international governments 
and private sources.
Some functional foods and drugs with identical targets available on the global market
Food Target Drugs
Enriched with 
phytosterol-stanolesters
Low density lipoprotein cholesterol Statins, ezetimibe
Containing bioactive 
peptides
Blood pressure Antihypertensive drugs (such as thiazide 
diuretics)
Containing melatonin Quality of sleep Benzodiazepines
Containing omega 3 
fatty acids
Depression Antidepressants
Triglycerides Fibrates
Containing β glucan Blood sugar values Insulin, oral hypoglycaemic drugs
Low density lipoprotein cholesterol Statins, ezetimibe
Containing prebiotics Bowel frequency Laxatives
Containing probiotics Immune functioning
Diarrhoea (wet stools) Loperamide
Crohn’s disease (under investigation) Mesalazine, corticosteroids
Containing extra calcium 
or vitamin D, or both
Bone health Alendronate, calcitonin, oestrogens
Containing protein or 
bioactive peptides
Obesity and type 2 diabetes Orlistat, rimonabant
Appetite
The efficacy of these foods on their targets has not necessarily been confirmed.
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Until now, postlaunch monitoring for functional 
foods has been erratic.25-27 The first attempt at such 
monitoring (for phytosterol enriched foods) found 
that people who buy the product eat less than was 
anticipated and that no serious adverse effects have 
been reported to manufacturers’ consumer care 
lines.19 27 Data were gathered at the household level 
only, however, so users were not characterised and it 
was not possible specifically to estimate exposure. 
Our unit has been mapping the effectiveness of 
phytosterol and stanol enriched margarine eaten by 
the Dutch population. The maximum effect seen 
over five years was stabilisation of total cholesterol 
values rather than the slight increase usually seen 
with age. Although this effect is modest, it can still 
reduce the risk of coronary heart disease and provide 
health benefits in the general population.24 These 
observations support the inclusion of effectiveness 
in the postlaunch monitoring programme. A future 
topic for research would be to evaluate the effec-
tiveness of adding functional foods to a traditional 
diet compared with altering the total diet according 
to dietary guidelines. This single example suggests 
that we need to invest more in finding out what 
functional foods can contribute to individual and 
public health in relation to the promises made by 
manufacturers. 
Contributors and sources: The authors are experts in postlaunch 
monitoring of functional foods (NdJ, MCJW, MCO, HV) and medicines (OHK, 
HGML). This draft was written �y NdJ, OHK, and MCJW, with comments 
�y HV, MCO, and HGML. Background studies that underpin the views 
presented in this paper were carried out �y all authors. NdJ is guarantor.
Funding: The Netherlands Organisation for Health Research and 
Development (ZonMW) is acknowledged for funding the PLM research and 
supporting MCJ Wolfs (grant num�er 014-12-010).
Competing interests: None declared.
Provenance and peer review: Non-commissioned; peer reviewed.
1 Pletscher W. Functional food: a growing and not clearly controlled 
market with a risk potential ranging from a food to a drug. Swiss Med 
Wkly 2004;134:367-8.
2 European Commission. Novel foods legislation. 2007 http://europa.
eu.int/comm/food/food/biotechnology/novelfood/legisl_en.htm
3 Aggett PJ, Antoine JM, Asp NG, Bellisle F, Contor L, Cummings JH, et al. 
PASSCLAIM: consensus on criteria. Eur J Nutr 2005;44(suppl 1):i5-30.
4 European Commission. Health and nutrition claims. http://ec.europa.
eu/food/food/labellingnutrition/claims/index_en.htm
5 Gilbert D, Whalley T, New B. Lifestyle medicines. BMJ 2000;321:1341-
4.
6 Pariza MW. Functional foods: technology, functionality, and health 
benefits. Nutr Today 1999;34:3.
7 Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration 
and death from suicide in men: Paris prospective study I. BMJ 
1996;313:649-51.
8 Leatherhead Food International. The international market for functional 
foods. Market report leaflet. June 2006. www.leatherheadfood.com/lfi/
pdf/ffoods2.pdf.  
9 Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched  
with three different levels of vegetable oil sterols and the degree 
of cholesterol lowering in normocholesterolaemic and mildly 
hypercholesterolaemic subjects. Eur J Clin Nutr 1999;53:319-27.
10 Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, et al. 
Efficacy and safety of plant stanols and sterols in the management of 
blood cholesterol levels. Mayo Clin Proc 2003;78:965-78.
11 Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of 
cardiovascular diseases. Ann Med 2004;36:126-34.
12 Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction 
of serum cholesterol with sitostanol-ester margarine in a mildly 
hypercholesterolemic population. N Engl J Med 1995;333:1308-12.
13 Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. 
Incremental reduction of serum total cholesterol and low-density 
lipoprotein cholesterol with the addition of plant stanol ester-
containing spread to statin therapy. Am J Cardiol 2000;86:46-52.
14 Patel MD, Thompson PD. Phytosterols and vascular disease. 
Atherosclerosis 2006;186:12-9.
15 Ratnayake W, Vasavour E. Potential health risks associated with large 
intakes of plant sterols. In: Dutta PC, ed. Plant sterols: analytical, 
nutritional and safety aspects as functional food components. New 
York: Marcel Dekker, 2004:365-96.
16 Home Health Canada. Health Canada advises that Becel Pro-activ 
not approved for sale. Oct 2001. www.hc-sc.gc.ca/ahc-asc/media/
advisories-avis/2001/2001_106_e.html. 
17 Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. 
Long term persistence with statin treatment in daily medical practice. 
Heart 2004;90:1065-6.
18 Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, 
Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start 
of therapy. Br J Clin Pharmacol 2005;60:83-9.
19 Scientific Committee on Food. Opinion of the Scientific Committee on 
Food on a report on post launch monitoring of “yellow fat spreads with 
added phytosterol esters.” Brussels: SCF, 2002.
20 Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy 
and herbal medicines: the risk of drug interaction. Int J Cardiol 
2005;98:1-14.
21 Ohnishi N, Yokoyama T. Interactions between medicines and functional 
foods or dietary supplements. Keio J Med 2004;53:137-50.
22 de Jong N, Fransen HP, van den Berg SW, Ocké MC. Postlaunch 
monitoring of functional foods—methodology development (III), report 
number 350030006. Bilthoven: RIVM, 2005.
23 de Jong N, Zuur A, Wolfs MCJ, Wendel-Vos GCW, van Raaij JMA, Schuit 
AJ. Exposure and effectiveness of phytosterol- and stanol-enriched       
margarines. Eur J Clin Nutr 2007 Feb 14Epub ahead of print.
24 Wolfs M, de Jong N, Ocké MC, Verhagen H,  Verschuren WMM. 
Effectiveness of customary use of phytosterol/-stanol enriched 
margarines on blood cholesterol lowering. Food Chem Toxicol 
2006;44:1682-8.
25 Allgood GS, Kuter DJ, Roll KT, Taylor SL, Zorich NL. Postmarketing 
surveillance of new food ingredients: results from the program with the 
fat replacer olestra. Regul Toxicol Pharmacol 2001;33:224-33.
26 Butchko HH, Stargel WW. Aspartame: scientific evaluation in the 
postmarketing period. Regul Toxicol Pharmacol 2001;34:221-33.
27 Lea LJ, Hepburn PA. Safety evaluation of phytosterol-esters. Part 9: 
results of a European post-launch monitoring programme. Food Chem 
Toxicol 2006;44:1213-22.
SuMMARY pOINTS
Functional foods are 
designed to meet 
consumers’ needs and 
lifestyle wishes and 
may be used as self 
medication
EU regulations focus 
on the warrant of safety 
before a functional food 
reaches the market
Postlaunch monitoring is 
needed to assess whether 
functional foods are 
safe and effective under 
customary conditions 
of use
Food
database
Passive signalling of
consumer complaints (1)
Active signalling of effects on health
on the basis of investigation of data (2)
Supplements
database
Assessment of
dietary intake
Assessment of nutritional
and health status
Postlaunch monitoring of effects on health
Assessment of the relevance of data from 1 and 2
Measurement of effects on health at the population or group level
Balancing beneficial and hazardous effects (benefit-risk analyses)
Risk-benefit management
Postlaunch monitoring programme
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